Drug intelligence / Profile preview

SR-1891

Development stage: Preclinical
Lead developer: IRCCS Ospedale San Raffaele
Modality: Small Molecules
Administration: Subcutaneous

Overview

SR-1891 is an ultrapotent, long-acting capsid assembly modulator (CAM) being developed for the treatment of chronic hepatitis B virus (HBV) infection. It exhibits sub-nanomolar in vitro anti-HBV activity and is designed for subcutaneous administration. In preclinical mouse models of chronic hepatitis B, a single subcutaneous dose of SR-1891 demonstrated sustained, multi-log reductions in serum HBV DNA and RNA, outperforming daily oral entecavir for at least 7 weeks without causing liver injury or ALT elevations.

Targets

HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on SR-1891.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SR-1891.